Trevena Announces Publication Highlighting Risk / Benefit Analysis of OLINVYK® in Pain and Therapy
August 10, 2021 07:00 ET
|
Trevena Inc.
CHESTERBROOK, Pa., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena to Release Second Quarter 2021 Financial Results on August 12th, 2021
August 09, 2021 07:00 ET
|
Trevena Inc.
CHESTERBROOK, Pa., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Announces First Patient Enrolled in NIH-Funded ACTIV-4 Host Tissue Trial of TRV027 for COVID-19
July 26, 2021 07:00 ET
|
Trevena Inc.
CHESTERBROOK, Pa., July 26, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Announces Two Leading Independent Proxy Advisory Firms Recommend Shareholders Vote “For” All Proposals Ahead of Special Meeting of Stockholders
July 23, 2021 07:00 ET
|
Trevena Inc.
CHESTERBROOK, Pa., July 23, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Announces Publication of OLINVYK® Health Economic Model in Journal of Comparative Effectiveness Research
July 12, 2021 07:00 ET
|
Trevena Inc.
Models demonstrate substantial overall cost savings for hospitals when using OLINVYK compared to IV morphine in postoperative care CHESTERBROOK, Pa., July 12, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc....
Trevena Announces First Patient Enrolled in OLINVYK® Phase 3 Trial in China in Partnership with Jiangsu Nhwa Pharmaceutical
July 08, 2021 07:10 ET
|
Trevena Inc.
Nhwa is conducting and funding this study to support NDA regulatory filing in China Trevena expects to receive approval and commercialization milestones, and a 10% royalty on net sales in China ...
Trevena Announces Initiation of OLINVYK® Respiratory Physiology Study Including Elderly / Obese Subjects
July 07, 2021 07:00 ET
|
Trevena Inc.
-- Study is evaluating the role of age and weight in a comparative analysis of the effect of OLINVYK and morphine on respiratory function Led by world-renowned research group, utilizing an...
Trevena Added to Russell 2000®, Russell 3000®, and Russell Microcap® Indexes
June 28, 2021 07:00 ET
|
Trevena Inc.
CHESTERBROOK, Pa., June 28, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
Trevena Announces Presentations of OLINVYK® Health Economic Models at ISPOR 2021
May 19, 2021 07:00 ET
|
Trevena Inc.
-- Models demonstrate substantial overall cost savings for hospitals when using OLINVYK compared to IV morphine in postoperative care -- CHESTERBROOK, Pa., May 19, 2021 (GLOBE NEWSWIRE) --...
Trevena Announces Presentation of OLINVYK® Respiratory Safety Data in High-Risk Patients at the 46th Annual ASRA Meeting
May 12, 2021 07:00 ET
|
Trevena Inc.
-- Elderly and obese patients receiving OLINVYK are not at increased risk for respiratory depression, compared to younger and non-obese patients, based on exploratory analysis -- CHESTERBROOK, Pa.,...